Jingda Bio

Name

Jingda Bio

Legal name

北京景达生物科技有限公司

Website

https://jingdabio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Cell Therapy Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

NK Cell Therapies (HLAAABAD)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• CAR-NK cell therapy
• NK cell immunotherapy
• Cell therapy drug development
• Allogeneic cell therapy
• Biopharmaceutical R&D

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

1. CAR-NK Cell Therapy Products: As a pre-commercial stage biotech company developing novel CAR-NK cell therapy drugs, Jingda Bio does not currently have revenue. The company is in the discovery and preclinical stage with multiple candidates in development. Future revenue is expected to come from commercializing NK/CAR-NK cell therapy products for cancer treatment, targeting both hematological malignancies and solid tumors.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Jingda Bio is a biopharmaceutical company that develops universal (allogeneic) NK and CAR-NK cell therapy drug candidates for the treatment of hematological malignancies and solid tumors. The company is currently in the pre-clinical/discovery stage with a pipeline including NKJD001 (multiple myeloma), NKJD002 (NKG2D, stem cell tumors), NKJD003 (BCMA), and NKJD004 (PD1Ab combination for non-small cell lung cancer), supported by proprietary NK cell expansion, viral transduction, gene editing, and single-cell quality control platforms.

Product overview

Jingda Bio is a CAR-NK cell therapy drug development company offering a pipeline of allogeneic NK and CAR-NK cell drug candidates. The company's core offerings include four pipeline candidates (NKJD001-004) targeting hematological malignancies like multiple myeloma and solid tumors including non-small cell lung cancer. These candidates range from discovery to preclinical stages. The company also provides technology platform services for NK cell development, including cell expansion, viral transduction, gene editing, and quality control.

Differentiator

Problem solved

Functional benefit

Products and services

• NKJD001 (Allogeneic CAR-NK) Allogeneic CAR-NK cell therapy candidate for the treatment of multiple myeloma (a hematological malignancy), currently in the discovery/preclinical development stage.
• NKJD002 (NKG2D CAR-NK) CAR-NK cell therapy candidate targeting the NKG2D receptor for the treatment of stem cell tumors (干细胞瘤), currently in the discovery/preclinical development stage.
• NKJD003 (BCMA CAR-NK) CAR-NK cell therapy candidate targeting the B-cell maturation antigen (BCMA) for hematological malignancy treatment, currently in the discovery/preclinical development stage.
• NKJD004 (PD1Ab Combination CAR-NK) CAR-NK cell therapy candidate combining PD1 antibody with NK cells for the treatment of non-small cell lung cancer (NSCLC), currently in the discovery/preclinical development stage.
• Universal NK and CAR-NK Cell Drug Development Platform Integrated technology platform for the development of universal (allogeneic) NK and CAR-NK cell drugs, comprising the LAGE-NK feeder-free NK cell expansion platform, SBVCT-VD viral transduction platform, C-TRAGs NK cell gene editing platform, and the HuluFish single-cell level quality control platform, supporting the full CAR-NK development cycle from cell screening and construction to expansion, transduction, and detection.

Quantifiable outcome

• NK cells show superior safety profile compared to CAR-T in early clinical studies, with lower risk of cytokine release syndrome (CRS) and neurotoxicity
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• Beijing WuJiahe Gene Technology Co., Ltd. (五加和基因)minorStrategic or Co-development Partner · 22 December 2021Dr. Dong Xiaoyan, founder of WuJiahe Gene, was appointed as senior consultant to Jingda Bio. WuJiahe Gene is a national high-tech enterprise specializing in viral vector system research for nearly 30 years, originating from the State Key Laboratory of Viral Gene Engineering at the Institute of Virology, Chinese Academy of Preventive Medicine. The consulting arrangement brings expertise in gene therapy viral vectors to support Jingda Bio's CAR-NK development.
• Beijing TianGuangShi Biotechnology Co., Ltd. (天广实生物)coreStrategic or Co-development Partner · 8 November 2021Strategic cooperation for NK cell and ADCC-enhanced antibody combination therapy development. The partnership focuses on combining Jingda Bio's universal NK cells with TianGuangShi's next-generation CD20 antibody (MIL62) and ADCC-enhanced Claudin18.2 antibody (MIL93) for pre-clinical and clinical research in hematological and solid tumor treatment. The collaboration leverages the biological mechanism where NK cells enhance antibody-dependent cellular cytotoxicity (ADCC), improving targeted tumor cell killing efficiency.
• Pixel Biotech GmbH (图维生物)coreTechnology or Integration · 17 September 2021Strategic cooperation to introduce Pixel Biotech's HuluSCOPE and HuluFISH single-molecule nucleic acid digital quantification technology for cell gene therapy drug quality control. This partnership upgrades cell gene therapy quality control from traditional population average measurement to precise single-cell single-molecule measurement, enabling demonstration of heterogeneity in cell gene drug manufacturing and improving the effectiveness and safety of Jingda Bio's cell therapy drugs. Pixel Biotech is a DKFZ (German Cancer Research Center) spin-off company.
• Beijing Yimiao Shenzhou Medical Technology Co., Ltd. (艺妙神州)coreStrategic or Co-development Partner · 6 August 2021CAR-NK strategic cooperation agreement signed to leverage Yimiao Shenzhou's CAR-T development expertise and proprietary gene cell drug R&D and industrialization platform. Yimiao Shenzhou has the only independent domestic gene cell drug R&D and industrialization platform in China with full core technology for CAR-T preparation, while Jingda Bio brings expertise in NK cell large-scale culture. The partnership aims to accelerate the development and commercialization of CAR-NK cell innovative drugs for malignant tumor treatment.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Shoreline Biosciences: Developer of engineered allogeneic NK cell therapies using iPSC-derived NK cells. Closely parallels Jingda's mission to deliver universal NK cell products at scale with gene-edited enhanced functionality.
• Nkarta Therapeutics: US clinical-stage biotech developing allogeneic, off-the-shelf CAR-NK cell therapies for hematologic malignancies and solid tumors—directly overlapping Jingda Bio's allogeneic NK and CAR-NK pipeline and targeting similar BCMA and other heme indications.
• Fate Therapeutics: Pioneer in iPSC-derived NK and T-cell therapies with an off-the-shelf, multiplexed-engineering platform. Directly comparable to Jingda in cell-therapy modality, allogeneic positioning, and use of gene editing to enhance NK cell function.

Broad incumbents

• Cellectis: French clinical-stage gene-editing and allogeneic CAR-cell therapy company. Comparable to Jingda on the enabling technology side (gene editing, viral transduction for cell engineering) and as a platform incumbent in off-the-shelf cell therapy.
• Allogene Therapeutics: Pioneering allogeneic CAR-T leader pursuing off-the-shelf cell therapy at scale. Comparable in platform approach (allogeneic, universal cell therapy) and indication overlap (hematologic malignancies), and serves as the broader incumbent benchmark for CAR-NK players including Jingda.

Emerging players

• Century Therapeutics: Clinical-stage company developing iPSC-derived NK and T-cell therapies with multiplexed gene editing. Comparable in modality (engineered NK/CAR-NK) and allogeneic platform approach, though broader across T-cell programs as well.

Regional players

• Yimiao Shenzhou (ImmunoChina): Beijing-based CAR-T developer with what Jingda describes as China's only independent gene-cell drug industrialization platform. Direct regional peer and named co-development partner for Jingda's CAR-NK program.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Jingda Bio